Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer
Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Trivadi S. Ganesan(Churchill Hospital), S. Muthuramalingam(Churchill Hospital), Frances R. Balkwill(Queen Mary University of London), Kulwinder Kaur(Churchill Hospital), Susan Wilner(Churchill Hospital), Cheng Han(Churchill Hospital), Susan Hoare(Queen Mary University of London), Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust)
Cited by 166
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
“Re-educating” tumor-associated macrophages by targeting NF-κB
|The Journal of Experimental Medicine|2008|780